NCT00002138View on ClinicalTrials.gov

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Sarcoma, KaposiHIV Infections
Interventions
DRUG

Tecogalan sodium

Trial Locations (1)

94110

Univ of California at San Francisco Gen Hosp, San Francisco

Sponsors
All Listed Sponsors
lead

Daiichi Pharmaceuticals

INDUSTRY

NCT00002138 - A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | Biotech Hunter | Biotech Hunter